Simvastatin Mitigates Kidney Injury via Inhibition of the TNF-α/α-SMA Signaling Pathway in a Subtotal Nephrectomy...

Area of Science:

• Nephrology
• Pharmacology
• Molecular Biology

Background:

• Subtotal nephrectomy (SNx) is a model for chronic kidney disease, characterized by inflammation and fibrosis.
• Understanding the molecular mechanisms underlying SNx-induced renal damage is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the renoprotective effects of simvastatin in a mouse model of subtotal nephrectomy.
• To analyze the role of key mediators of inflammation and fibrosis, specifically TNF-α and α-SMA, in simvastatin's protective action.

Main Methods:

• Thirty male Swiss mice underwent subtotal nephrectomy and were divided into five groups: sham, nephrectomy, and three simvastatin-treated groups (5, 10, 20 mg/kgBW).
• Renal function was assessed via serum creatinine, BUN, and proteinuria.
• Interstitial fibrosis was quantified using Sirius red staining.
• Expressions of TNF-α and α-SMA were evaluated using real-time PCR and immunohistochemistry, respectively.

Main Results:

• Subtotal nephrectomy led to impaired renal function, increased interstitial fibrosis, and elevated TNF-α and α-SMA expression.
• Simvastatin treatment dose-dependently improved renal function markers (creatinine, proteinuria) and significantly attenuated interstitial fibrosis.
• Simvastatin also dose-dependently decreased TNF-α and α-SMA expression, with α-SMA directly contributing to fibrosis.

Conclusions:

• Simvastatin exhibits renoprotective effects in the subtotal nephrectomy model.
• These effects are likely mediated by the inhibition of the TNF-α/α-SMA signaling pathway.
• α-SMA plays a critical role as a mediator linking inflammation to renal fibrosis.